Pivotal preclinical trial of the spheroid reservoir bioartificial liver
Open accessThe DOI matches its Crossref record.
Abstract
Background & Aims The neuroprotective effect of the spheroid reservoir bioartificial liver (SRBAL) was evaluated in a porcine model of drug-overdose acute liver failure (ALF). Methods Healthy pigs were randomized into three groups (standard therapy (ST) alone, ST + No-cell device, ST + SRBAL device) before placement of an implantable intracranial pressure (ICP) monitor and a tunneled central venous catheter. One week later, pigs received bolus infusion of the hepatotoxin D-galactosamine and were followed for up to 90 hours. Results At 48 hours, all animals had developed encephalopathy and biochemical changes confirming ALF; extracorporeal treatment was initiated and pigs were observed up to 90 hours after drug infusion. Pigs treated with the SRBAL, loaded with porcine hepatocyte spheroids, had improved survival (83%, n=6) compared to ST alone (0%, n=6, p=0.003) and No-cell device therapy (17%, n=6, p=0.02). Ammonia detoxification, peak levels of serum ammonia and peak ICP, and pig survival were influenced by hepatocyte cell dose, membrane pore size and duration of SRBAL treatment. Hepatocyte spheroids remained highly functional with no decline in mean oxygen consumption from initiation to completion of treatment. Conclusions The SRBAL improved survival in an allogeneic model of drug-overdose ALF. Survival correlated with ammonia detoxification and ICP lowering indicating that hepatocyte spheroids prevented the cerebral manifestations of ALF (brain swelling, herniation, death). Further investigation of SRBAL therapy in a clinical setting is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A decade of progress in liver regenerative medicine
Zhang, J., Zhao, X., Liang, L., Li, J., Demirci, U., & Wang, S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.027 · Cited by 111
Chen, H. S., Joo, D. J., Shaheen, M., Li, Y., Wang, Y., Yang, J., Nicolas, C. T., Predmore, K., Amiot, B., Michalak, G., et al. (2019) · Hepatology · doi:10.1002/hep.30184 · Cited by 77
“(6-8) One such device is the spheroid reservoir bio-artificial liver (SRBAL), which showed a survival benefit and was associated with both a significant lowering of blood ammonia levels and a neuroprotective effect with reduced cerebral edema formation in a drug-induced ALF model.(9) In addition to ammonia detoxificat…”
BackgroundMethodResultInfluentialSelf-citationFirst-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure
Zwirner, S., Abu Rmilah, A. A., Klotz, S., Pfaffenroth, B., Kloevekorn, P., Moschopoulou, A. A., Schuette, S., Haag, M., Selig, R., Li, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.023 · Cited by 65
Self-citationEngineering Liver Microtissues for Disease Modeling and Regenerative Medicine
Huang, D. (., Gibeley, S. B., Xu, C., Xiao, Y., Celik, O., Ginsberg, H. N., & Leong, K. W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909553 · Cited by 65
Bioinspired Artificial Liver System with hiPSC‐Derived Hepatocytes for Acute Liver Failure Treatment
Wang, J., Ren, H., Liu, Y., Sun, L., Zhang, Z., Zhao, Y., & Shi, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101580 · Cited by 49
Metadata
- Authors
- Glorioso, J. M., Mao, S. A., Rodysill, B., Mounajjed, T., Kremers, W. K., Elgilani, F., Hickey, R. D., Haugaa, H., Rose, C. F., Amiot, B., & Nyberg, S. L.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 63
- Issue
- 2
- Pages
- 388-398
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1925332710
- Cited by
- 88
- References
- 0
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pivotal preclinical trial of the spheroid reservoir bioartificial liver. https://app.cochat.ai/papers/10.1016/j.jhep.2015.03.021
- The paper
- Glorioso, J. M., Mao, S. A., Rodysill, B., Mounajjed, T., Kremers, W. K., Elgilani, F., Hickey, R. D., Haugaa, H., Rose, C. F., Amiot, B., & Nyberg, S. L. (2015). Pivotal preclinical trial of the spheroid reservoir bioartificial liver. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2015.03.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.